1.
Lung Cancer
; 95: 15-6, 2016 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27040846
RESUMO
We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.